title: Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy.
authors.forename: Amélie
authors.initials: A
authors.lastname: Florent
authors.forename: Christine
authors.initials: C
authors.lastname: Albert
authors.forename: Damien
authors.initials: D
authors.lastname: Giacchero
authors.forename: Christian
authors.initials: C
authors.lastname: Roux
authors.forename: Liana
authors.initials: L
authors.lastname: Euller-Ziegler
mesh_terms: D000069594:Abatacept; D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D012008:Recurrence; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D000069594:Abatacept; D000068879:Adalimumab